TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34143831
Drug: Biological larviciding
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological larviciding with Bacillus thuringiensis israelensis (full or guided intervention)
Study: 32653604
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine injection (0.5 %, 5 mg/mL) at a dose of 4 ml for the umbilicus and 2 ml for each 5‐mm ancillary trocar site
Study: 32653604
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine injection (0.5 %, 5 mg/mL)
Study: 32653604
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bupivacaine administered)
Study: 35803290
Drug: CAS + IMD (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS + IMD (1200 mg subcutaneous injection)
Study: 34423033
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg per day for 12 weeks)
Study: 34423033
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg per day for 12 weeks)
Study: 36314057
Drug: Dexamethasone 12
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg daily
Study: 36190994
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg daily
Study: 32538495
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg/kg
Study: 34506086
Drug: Complete decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete decongestive therapy (CDT)
Study: 36927419
Drug: Low-dose CT-guided
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT-guided biopsy
Study: 32503093
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 600 mg administered over a 2-hour infusion
Study: 32503093
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 600 mg administered over a 3.5-hour infusion (conventional)
Study: 33106280
Drug: Transmuscular quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmuscular quadratus lumborum (TQL) block with ropivacaine 60 mL 0.375%
Study: 33106280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline 60 mL)
Study: 33050920
Drug: 3D-conformal radiotherapy
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-conformal radiotherapy with sequential boost (Arm B: whole breast 28 × 1.8 Gy, boost 8 × 2 Gy)
Study: 37093196
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg once daily
Study: 34781936
Drug: Telephone health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone health coaching (THC) sessions (monthly, average 30 min for 12 months)
Study: 34922724
Drug: Tramadol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (75 mg) + Dexketoprofen (25 mg)
Study: 35026038
Drug: Web-based brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based brief intervention program for recording daily alcohol consumption for 4 weeks
Study: 33075775
Drug: Fluoride dentifrice
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride dentifrice with 5,000 µg F/g
Study: 33075775
Drug: Fluoride dentifrice
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride dentifrice with 1,300 µg F/g
Study: 33075775
Drug: Fluoride dentifrice
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride dentifrice with 0 µg F/g
Study: 33075775
Drug: Fluoride dentifrice
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride dentifrice with 700 µg F/g
Study: 32522095
Drug: Ticagrelor (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (loading dose: 180 mg, maintenance dose: 90 mg bid)
Study: 32522095
Drug: Clopidogrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading dose: 300 mg, maintenance dose: 75 mg qd)
Study: 34593298
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin nasal spray
Study: 35108610
Drug: EFV 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV 400 mg
Study: 35436807
Drug: Rim arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rim arterial phase hyperenhancement and enhanced capsule
Study: 33186308
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block using 10 ml 0.35% ropivacaine (group MINB)
Study: 34411275
Drug: Bundled care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bundled care program including povidone-iodine skin preparation, nasal decolonization, iodine-alcohol surgical prepping solution, iodophor-impregnated incise drapes, forced-air warming blankets, and negative pressure wound therapy.
Study: 35653595
Drug: Combined bleaching
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bleaching (desensitizing gel for 10 minutes, in-office bleaching with 35% hydrogen peroxide for 2×15 minutes, followed by at-home bleaching with 4% hydrogen peroxide for 2×30 minutes for 21 days)
Study: 32729099
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg/bid from 48 hours before to 24 hours after the procedure with fixed maximal voltage (Group C)
Study: 35716457
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) added to ibuprofen + paracetamol + pregabalin
Study: 35716457
Drug: No Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Pentoxifylline (Control) with ibuprofen + paracetamol + pregabalin
Study: 38247384
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) treatment
Study: 34013489
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone monitoring only (Control Group)
Study: 33988155
Drug: Pethidine 50
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 50 mg intramuscular injection
Study: 34251533
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment (660 nm, 100mW, 177 J/cm2, 5 s, 0.5 J) twice a week for 30 days
Study: 34919073
Drug: VK2+VD3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK2+VD3 group (received vitamin K2, vitamin D3, and calcium treatment)
Study: 32556827
Drug: Menopausal Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal Hormone Therapy (MHT)
Study: 32556827
Drug: Transdermal, newer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal, newer low-dose oral therapies, and SERM therapies
Study: 33183463
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CT)
Study: 32358375
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine cooperative therapy on the basis of conventional Western medicine
Study: 35073968
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (25 mg/kg every 6 hours for up to 96 hours)
Study: 35073968
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous 5% dextrose)
Study: 32188702
Drug: ?GalCer-pulsed APCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ?GalCer-pulsed APCs administered intravenously four times
Study: 34913980
Drug: Oral azithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin, 10 mg/kg once daily for 3 days
Study: 33983395
Drug: Level B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level B (oxaliplatin 104 mg/m2, capecitabine 500 mg/m2)
Study: 33983395
Drug: Level C
Normalized name: Precision Tri-Level Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level C (oxaliplatin 78 mg/m2, capecitabine 375 mg/m2)
Study: 36297065
Drug: Wheat biscuits
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat biscuits enriched with L-arginine (ArgB)
Study: 34097705
Drug: Mathematical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mathematical model of heparin clearance for protamine dosing
Study: 34097705
Drug: Fixed ratio
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed ratio of 1 mg of protamine for every 100 IU of heparin
Study: 34030591
Drug: US-guided percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided percutaneous catheter placement and hydrostatic pressure irrigation combined with oral antibiotics
Study: 32475458
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 7.5 mg Cd/kg feed
Study: 32475458
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 15 mg Cd/kg feed
Study: 32475458
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 30 mg Cd/kg feed
Study: 32475458
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 60 mg Cd/kg feed
Study: 35263688
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy
Study: 32956651
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg daily
Study: 32430334
Drug: Atezolizumab (anti-PD-L1)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (anti-PD-L1) monotherapy
Study: 34881553
Drug: Caffeine (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400mg dose of caffeine anhydrous)
Study: 38448895
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy (GCBT)
Study: 33358119
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam lysine plus IV colistimethate (AZLI+IV)
Study: 33358119
Drug: Dual IV
Normalized name: Dual IV Stand Adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual IV antibiotics (IV+IV)
Study: 33436018
Drug: IBM score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBM score based on pre‐treatment contrast‐enhanced CT
Study: 35996967
Drug: Emblica officinalis
Normalized name: Emblica officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emblica officinalis extract (EOE) 2 g
Study: 35996967
Drug: Emblica officinalis
Normalized name: Emblica officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emblica officinalis extract (EOE) 1 g
Study: 35100192
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of inspiratory support to obtain transdiaphragmatic pressure swings in the predefined 'diaphragm-protective' range (3-12 cm H2O)
Study: 32611866
Drug: Clove-papaya based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clove-papaya based anesthetic gel
Study: 36263451
Drug: Daily emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emollient plus standard skin-care advice
Study: 34015940
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily for 6 months (n=642)
Study: 32359142
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g PRO
Study: 32359142
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g PRO
Study: 32359142
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g PRO
Study: 32359142
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g PRO
Study: 35303461
Drug: OptiMA strategy
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMA strategy (a single programme for both severe acute malnutrition and moderate acute malnutrition using RUTF at a decreasing dose as MUAC and weight increased)
Study: 35303461
Drug: Standard strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard strategy (one programme for severe acute malnutrition using ready‐to‐use therapeutic food [RUTF] at an increasing dose as weight increased, another for moderate acute malnutrition using a fixed dose of ready‐to‐use supplementary food [RUSF])
Study: 35996891
Drug: Pilates-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates-based exercise classes (four-week, twice-weekly)
Study: 32319392
Drug: Low-dose bortezomib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bortezomib (0.7 mg/m2) + cyclophosphamide (0.5 g/m2) + dexamethasone
Study: 32319392
Drug: Standard-dose bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose bortezomib (1.3 mg/m2) + cyclophosphamide (0.5 g/m2) + dexamethasone
Study: 32319392
Drug: Bortezomib (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (0.7 mg/m2) + dexamethasone
Study: 32319392
Drug: Low-dose bortezomib-based
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bortezomib-based therapy
Study: 35875695
Drug: Dihydrocapsiate (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocapsiate (12 mg)
Study: 36152013
Drug: Non-cultured epidermal
Normalized name: omidubicel
DrugBank: Omidubicel (DB17132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cultured epidermal cell suspension (ECS)
Study: 36152013
Drug: Hair follicle
Normalized name: BIOTIN 2 g in 30 mL TOPICAL OIL [Reactivate Hair Follicles]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair follicle cell suspension (HFCS)
Study: 34236011
Drug: GB222 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB222 (1 mg/kg)
Study: 34236011
Drug: Bevacizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1 mg/kg)
Study: 33471112
Drug: Restarting golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Restarting golimumab treatment
Study: 33471112
Drug: Step-down strategy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down strategy to MTX monotherapy
Study: 38824941
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy
Study: 35328990
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid and hyaluronic acid-based gel
Study: 32100647
Drug: Multi-nutrient (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient (1 g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20 mg d‐α tocopherol, 1 mg folic acid and 20 g vitamin B12 per day)
Study: 32100647
Drug: Multi-nutrient and
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient and exercise (spin class twice per week)
Study: 34174970
Drug: Control (drug-free)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (drug-free)
Study: 35985545
Drug: ETV+BRC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV+BRC and ETV monotherapy
Study: 34732148
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise intervention (60-min sessions, twice a week for 6 months)
Study: 33915788
Drug: Modified low-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified low-protein formula (mLP) (1.7 g protein/100 kcal)
Study: 33915788
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula (CTRL) (2.1 g protein/100 kcal)
Study: 33306026
Drug: Drink Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink Less app with daily 11 AM notification
Study: 35128872
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine treatment and enema with tuihuang mixture
Study: 34383222
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 7% sodium chloride solution
Study: 32249850
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lutein supplementation (beeswax group)
Study: 32249850
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lutein supplementation (glycerol fatty acid esters group)
Study: 35378068
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg by subcutaneous injection every 2 weeks)
Study: 32758455
Drug: Debio 1143
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 1143 (200 mg per day on days 1-14 of 21-day cycles, for three cycles)
Study: 32758455
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mg/mL, administered at the same dosing schedule)
Study: 38175837
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (cMDA)
Study: 34753540
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (10 mg/kg maintenance dose)
Study: 34753540
Drug: Low-dose caffeine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose caffeine (5 mg/kg maintenance dose)
Study: 33826415
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with IPC plus LLLT
Study: 33826415
Drug: IPC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPC therapy alone
Study: 37023069
Drug: Cost-effectiveness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effectiveness of treatment
Study: 32648397
Drug: Needle-knife therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-knife therapy at cervical spine area, acupuncture at specific acupoints, sodium hyaluronate eye drops (1 drop 5-6 times a day) for 3 courses (1 week each).
Study: 33637882
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy)
Study: 33637882
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy) in patients with active disease
Study: 34598692
Drug: HOP‐UP‐PT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOP‐UP‐PT program (Home‐based Older Persons Upstreaming Prevention‐Physical Therapy) delivered by physical therapists over nine encounters (six in-person, three telerehabilitation) spanning seven months.
Study: 32583295
Drug: Oliceridine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliceridine (all doses)
Study: 35196591
Drug: 0.1% nepafenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% nepafenac eye drops, thrice daily for 2 weeks
Study: 35196591
Drug: 0.09% bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% bromfenac eye drops, twice daily for 2 weeks
Study: 32112591
Drug: Intralesional 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 5‐fluorouracil (5‐FU) injections
Study: 32112591
Drug: Both 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 5‐FU and TAC injections
Study: 34677593
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone
Study: 32469388
Drug: HIGH protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH protein diet (1.6 g protein/kg/d)
Study: 32469388
Drug: LOW protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW protein diet (0.5 g protein/kg/d)
Study: 32469388
Drug: NO protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO protein diet (0.15 g protein/kg/d)
Study: 32469388
Drug: Daily MyoPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily MyoPS rates during immobilization
Study: 32732142
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza vaccine (IIV3-BV)
Study: 32732142
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza vaccine (IIV3-BY)
Study: 34118255
Drug: Preparation up
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation up to size 25.04
Study: 34118255
Drug: Preparation up
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation up to size 25.06
Study: 34118255
Drug: Preparation up
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation up to size 30.04
Study: 34118255
Drug: Preparation up
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation up to size 30.06